1. Fahmi I. World Health Organization coronavirus disease 2019 (Covid-19) situation report. DroneEmprit. 2019.

2. Gerotziafas GT, Catalano M, Colgan M-P, Pecsvarady Z, Wautrecht JC, Fazeli B, et al. Guidance for the management of patients with vascular disease or cardiovascular risk factors and COVID-19: position paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. Thromb Haemost 2020; 120(12): 1597-628.

3. Boettler T, Marjot T, Newsome PN, Mondelli MU, Maticic M, Cordero E, et al. Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. JHEP Rep 2020; 2(5).

4. Wu L, O'Kane AM, Peng H, Bi Y, Motriuk-Smith D, Ren J. SARS-CoV-2 and cardiovascular complications: from molecular mechanisms to pharmaceutical management. Biochem pharmacol. 2020; 178: 114114

5. Trottein F, Sokol H. Potential causes and consequences of gastrointestinal disorders during a SARS-CoV-2 infection. Cell Rep 2020; 32(3): 107915.

6. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181(2): 271-80. e8.

7. Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z, et al. Characteristics of COVID-19 infection in Beijing. J Infect 2020; 80(4): 401-6.

8. Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect 2020; 9(1): 757-60.

9. Agrawal H, Das N, Nathani S, Saha S, Saini S, Kakar SS, Roy P. An assessment on impact of COVID-19 infection in a gender specific manner. Stem Cell Rev Rep. 2020; 17(1): 94-112.

10. Rahimi Z, Moradi M, Nasri H. A systematic review of the role of renin angiotensin aldosterone system genes in diabetes mellitus, diabetic retinopathy and diabetic neuropathy. Journal of research in medical sciences: J Res Med Sci 2014; 19(11): 1090.

11. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol 2020; 20(6): 355-62.

12. Beltrán-García J, Osca-Verdegal R, Pallardó FV, Ferreres J, Rodríguez M, Mulet S, et al. Oxidative stress and inflammation in COVID-19-associated sepsis: the potential role of anti-oxidant therapy in avoiding disease progression. Antioxidants (Basel) 2020; 9(10): 936.

13. Schönrich G, Raftery MJ. Neutrophil extracellular traps go viral. Front Immunol 2016; 7: 366.

14. Masso-Silva JA, Moshensky A, Lam MT, Odish M, Patel A, Xu L, et al. Increased peripheral blood neutrophil activation phenotypes and NETosis in critically ill COVID-19 patients. Clin Infect Dis 2021; ciab437.

15. Middleton EA, He XY, Denorme F, Campbell RA, Ng D, Salvatore SP, et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood 2020; 136(10): 1169-79.

16. Edler C, Schröder AS, Aepfelbacher M, Fitzek A, Heinemann A, Heinrich F, et al. Dying with SARS-CoV-2 infection—an autopsy study of the first consecutive 80 cases in Hamburg, Germany. Int J Legal Med 2020; 134(4): 1275-84.

17. Rabelo LA, Alenina N, Bader M. ACE2–angiotensin-(1–7)–Mas axis and oxidative stress in cardiovascular disease. Hypertens Res 2011; 34(2): 154-60.

18. Rana MM. Cytokine storm in COVID-19: Potential therapeutics for immunomodulation. JRCM 2020; 8(1): 38.

19. Cavezzi A, Troiani E, Corrao S. COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review. Clin Pract 2020; 10(2): 24-30.

20. Laforge M, Elbim C, Frère C, Hémadi M, Massaad C, Nuss P, et al. Tissue damage from neutrophil-induced oxidative stress in COVID-19. Nat Rev Immunol 2020; 20(9): 515-516.

21. Ji P, Zhu J, Zhong Z, Li H, Pang J, Li B, Zhang J. Association of elevated inflammatory markers and severe COVID-19: A meta-analysis. Med (Baltimore) 2020; 99(47).

22. Panigrahy D, Gilligan MM, Huang S, Gartung A, Cortés-Puch I, Sime PJ, et al. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19? Cancer Metastasis Rev. 2020; 39(2):337-40.

23. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou Cq, He JX, et al. Clinical characteristics of (2019) novel coronavirus infection in China. N Engl J Med 2020.

24. Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 8(5): 475-81.

25. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.

26. Yang M. Cell pyroptosis, a potential pathogenic mechanism of 2019-nCoV infection. Available at SSRN 2020; 3527420.

27. Yang Y, Peng F, Wang R, Guan K, Jiang T, Xu G, et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun 2020; 109: 102434.

28. Schultze JL, Aschenbrenner AC. COVID-19 and the human innate immune system. Cell 2021; 184(7): 1671-92.

29. Zhou Y, He C, Wang L, Ge B. Post‐translational regulation of antiviral innate signaling. Eur J Immunol 2017; 47(9): 1414-26.

30. Karki R, Sharma BR, Tuladhar S, Williams EP, Zalduondo L, Samir P, et al. Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes. Cell 2021; 184(1): 149.

31. Chen IY, Moriyama M, Chang MF, Ichinohe T. Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. Front Microbiol 2019; 10: 50.

32. Xu H, Chitre SA, Akinyemi IA, Loeb JC, Lednicky JA, McIntosh MT, et al. SARS-CoV-2 viroporin triggers the NLRP3 inflammatory pathway. Virology 2020.

33. Chan CM, Tsoi H, Chan WM, Zhai S, Wong CO, Yao X, et al. The ion channel activity of the SARS-coronavirus 3a protein is linked to its pro-apoptotic function. Int J Biochem Cell Biol 2009; 41(11): 2232-9.

34. Cagliani R, Forni D, Clerici M, Sironi M. Coding potential and sequence conservation of SARS-CoV-2 and related animal viruses. Infect Genet Evol 2020; 83: 104353.

35. Ahn M, Anderson DE, Zhang Q, Tan CW, Lim BL, Luko K, et al. Dampened NLRP3-mediated inflammation in bats and implications for a special viral reservoir host. Nat Microbiol. 2019; 4(5): 789-99.

36. Van den Berg DF, Te Velde AA. Severe COVID-19: NLRP3 inflammasome dysregulated. Front Immunol 2020; 11: 1580.

37. Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol Sin 2020; 35(3): 266-71.

38. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al (). Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005; 436(7047): 112-6.

39. Chakraborty S, Gonzalez J, Edwards K, Mallajosyula V, Buzzanco AS, Sherwood R, et al. Proinflammatory IgG Fc structures in patients with severe COVID-19. Nat Immunol 2021; 22(1): 67-73.

40. Zhang L, Zhang F, Yu W, He T, Yu J, Yi CE, et al. Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals. J Med Virol 2006; 78(1): 1-8.

41. Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H, et al . Anti–spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight 2019; 4(4).

42. Shattuck EC, Muehlenbein MP. Human sickness behavior: Ultimate and proximate explanations. Am J Phys Anthropol. 2015; 157(1): 1-18.

43. Lara PC, Macías-Verde D, Burgos-Burgos J (). Age-induced NLRP3 Inflammasome over-activation increases lethality of SARS-CoV-2 pneumonia in elderly patients. Aging Dis. 2020; 11(4): 756.

44. Latz E, Duewell P. NLRP3 inflammasome activation in inflammaging. Semin Immunol 2018; 40: 61-73.

45. Bertocchi I, Foglietta F, Collotta D, Eva C, Brancaleone V, Thiemermann C, Collino M. The hidden role of NLRP3 inflammasome in obesity‐related COVID‐19 exacerbations: lessons for drug repurposing. Br J Pharmacol 2020; 177(21): 4921-30.

46. López-Reyes A, Martinez-Armenta C, Espinosa-Valázquez R, Vázquez-Cárdenas P, Cruz-Ramos M, Gomez-Quiroz LE, Martínez-Nava GA. NLRP3 Inflammasome: the stormy link between obesity and COVID-19. Front Immunol 2020; 11: 2875.

47. Samadizadeh S, Masoudi M, Rastegar M, Salimi V, Shahbaz MB, Tahamtan A. COVID-19: Why does disease severity vary among individuals? Respir Med 2021: 106356.

48. Beltrán-García J, Osca-Verdegal R, Pallardó FV, Ferreres J, Rodríguez M, Mulet S. Sepsis and Coronavirus Disease 2019: Common Features and Anti-Inflammatory Therapeutic Approaches. Crit Care Med 2020.

49. Manzanares W, Dhaliwal R, Jiang X, Murch L, Heyland DK. Antioxidant micronutrients in the critically ill: a systematic review and meta-analysis. Crit Care 2012; 16(2): 1-13.

50. Acuña‐Castroviejo D, Escames G, Figueira JC, de la Oliva P, Borobia AM, Acuña‐Fernández C. Clinical trial to test the efficacy of melatonin in COVID‐19. J Pineal Res 2020; 69(3): e12683.

51. Carrasco C, Marchena AM, Holguín‐Arévalo MS, Martín‐Partido G, Rodríguez AB, Paredes SD, Pariente JA. Anti‐inflammatory effects of melatonin in a rat model of caerulein‐induced acute pancreatitis. Cell Biochem Funct 2013; 31(7): 585-90.

52. Cronje HT, Nienaber-Rousseau C, Zandberg L, De Lange Z, Green FR, Pieters M. Fibrinogen and clot-related phenotypes determined by fibrinogen polymorphisms: Independent and IL-6-interactive associations. PLoS One 2017; 12(11): e0187712.

53. Sidelmann JJ, Gram J, Jespersen J, Kluft C. Fibrin clot formation and lysis: basic mechanisms. Semin Thromb Hemost 2000; 26(6): 605-18.

54. Huang Y, Hua J, Yun C, W, Yang Y, Tao J, Deng X, et al. Tranilast directly targets NLRP 3 to treat inflammasome‐driven diseases. EMBO Mol Med 2018; 10(4): e8689.

55. Yang X, Yang LX, Wu J, Guo ML, Zhang Y, Ma SG. Treatment of lidocaine on subacute thyroiditis via restraining inflammatory factor expression and inhibiting pyroptosis pathway. J Cell Biochem 2019; 120(7): 10964-71.

56. Bode C, Peukert K, Schewe JC, Putensen C, Latz E, Steinhagen F. Tetracycline alleviates acute lung injury by inhibition of NLRP3 inflammasome. Eur Respir J 2019; 54: PA2175